Crossmark

Seeing the patient’s perspective: a guide to patient-reported outcome measures and minimal important differences in ophthalmic research

Crossref DOI link: https://doi.org/10.1038/s41433-022-01989-5

Published Online: 2022-02-23

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qasim, Anila

Devji, Tahira

Phillips, Mark R. https://orcid.org/0000-0003-0923-261X
Wykoff, Charles C.

Kaiser, Peter K. https://orcid.org/0000-0001-5126-045X
Thabane, Lehana https://orcid.org/0000-0003-0355-9734
Bhandari, Mohit https://orcid.org/0000-0001-9608-4808
Chaudhary, Varun https://orcid.org/0000-0002-9988-4146
,

Sivaprasad, Sobha

Kaiser, Peter

Sarraf, David

Bakri, Sophie J.

Garg, Sunir J.

Singh, Rishi P.

Holz, Frank G.

Wong, Tien Y.

Guymer, Robyn H.
License Information

Text and Data Mining valid from 2022-02-23

Version of Record valid from 2022-02-23
More Information

Article History

Received: 17 December 2021

Revised: 2 February 2022

Accepted: 14 February 2022

First Online: 23 February 2022

Competing interests

: AQ, TD, and MRP: nothing to disclose. CCW: consultant: Acuela, Adverum Biotechnologies, Inc., Aerpio, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, Bayer AG, Chengdu Kanghong Pharmaceuticals Group Co, Ltd, Clearside Biomedical, DORC (Dutch Ophthalmic Research Center), EyePoint Pharmaceuticals, Gentech/Roche, GyroscopeTx, IVERIC bio, Kodiak Sciences Inc., Novartis AG, ONL Therapeutics, Oxurion NV, PolyPhotonix, Recens Medical, Regeneron Pharmaceuticals, Inc., REGENXBIO Inc., Santen Pharmaceutical Co, Ltd, and Takeda Pharmaceutical Company Limited; research funds: Adverum Biotechnologies, Inc., Aerie Pharmaceuticals, Inc., Aerpio, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Inc., GyroscopeTx, Ionis Pharmaceuticals, IVERIC bio, Kodiak Sciences Inc., Neurotech LLC, Novartis AG, Opthea, Outlook Therapeutics, Inc., Recens Medical, Regeneron Pharmaceuticals, Inc., REGENXBIO Inc., Samsung Pharm Co, Ltd, Santen Pharmaceutical Co, Ltd, and Xbrane Biopharma AB—unrelated to this study. PKK: consultant: Novartis, Bayer, Biogen, Regeneron, Kanghong, Allergan, RegenxBio—unrelated to this study. LT: nothing to disclose. MB: research funds: Pendopharm, Bioventus, Acumed—unrelated to this study. VC: advisory board member: Alcon, Roche, Bayer, Novartis; Grants: Bayer, Novartis—unrelated to this study.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below